Operative blood loss and transfusions have different impairments as allergic reaction, disease transmission and immunologic dysfunction. Transfusions are also associate with wound and lung infection
after surgery and systemic recurrence in oncologic patients. To decrease the blood loss and red blood cell transfusion (RBCT) is mandatory in orthopedic oncology patients. Tranexamic acid (TXA) is drug used to
reduce the bleeding in non-oncologic orthopedic surgeries.
PURPOSE: 1)To determine blood loss in drainage and total blood loss as postoperative decrease in hemoglobin and hematocrit levels in patients with administration
of TXA.
2)To compare the effectiveness of TXA administered by three different biases during surgery in primary limb sarcomas.
3)To evaluate the safeness of the TXA in oncology patients with sarcoma
